Encube to buy anti-microbial brand Soframycin from Sanofi for Rs 125 cr

Topics Sanofi

Sanofi | Photo: Reuters
Topical products manufacturer Encube Ethicals said on Friday that it has agreed to buy popular topical anti-microbial brand Soframycin along with a portfolio of other brands for the India and Sri Lanka markets from Sanofi. The deal size is estimated to be around Rs 125 crore.

Apart from Soframycin, Encube will also acquire other legacy associated brands such as Sofradex (antibacterial cream), Sofracort (antibacterial eye and ear drops), Soframycin-Tulle (antibacterial cream) for India and Sri Lanka markets.

Sanofi shares ended day’s trade on the BSE at Rs 8299.95 apiece, up 1.5 percent.

Soframycin is a legacy brand for Sanofi with a history of more than 50-years in India. The brand also has a strong recall, and Soframycin along with the other associate brands acquired by Encube accounted for around 2.6 percent of Sanofi’s India sales in 2020.

Encube is a manufacturer of prescription and OTC skincare products globally, and this would be its initial steps to launch products with its own label in India.

Encube, which has been contract manufacturing the Soframycin skin cream for over 20 years, said it will vertically integrate the brand building a front-end presence in India.

“Encube’s focus of 23+ years in skincare research and manufacturing will be leveraged to make a house of skincare brands, starting with the deep-rooted legacy of Soframycin," said Mehul Shah, founder and managing director of Encube.

Rajaram Narayanan, managing director of Sano India said the company regularly assesses the best ways in which to serve patients. term road map," Narayanan said.

The transaction is expected to close within the next three months.

Wadia Ghandy & Co. served as legal advisors to Encube on the transaction.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel